Abstract: The invention relates to a packaging system for the in-situ preparation of cosmetic formulations which has a micromixer. This micromixer can be connected to one or more stock chambers.

Abstract: The invention relates to particles with an opalescent effect, which have a particle size in the range from 5 &mgr;m to 5000 &mgr;m, comprising monodisperse spheres having a diameter of 50 nm to 2 &mgr;m with a standard deviation of less than 5% in a packed and regularly ordered structure which is three-dimensional in terms of domains and is mechanically stabilized by physical or chemical modification.

Abstract: The invention relates to new thienothiophene derivatives, their use as semiconductors or charge transport materials, in optical, electrooptical or electronic devices like for example organic field effect transistors (FET or OFET) for thin film transistor liquid crystal displays and integrated circuit devices such as RFID tags, electroluminescent devices in flat panel displays, and in photovoltaic and sensor devices, and to a field effect transistor, light emitting device or ID tag comprising the thienothiophene derivatives.

Abstract: The present invention relates to a new catalyst system for fluorous biphasic catalysis processes which comprises functionalized polymeric beads, monodisperse SiO2 or SiO2 flakes associated with the catalyst. These functionalized particles are used as a support for catalysts in fluorous biphasic catalysis (FBC).

Abstract: Homeotropically oriented layers and films of liquid crystals especially on polymeric substrates. The layers and films, which also can be multi-layered films comprising a homeotropically aligned anisotropic film, are preparable by application of an orientation layer to the substrate. The orientation layer can be either an organic surfactant which is fixed in a matrix of a polymeric material or an inorganic thin layer such as aluminum or Al2O3.

Abstract: A device for aligning a guide template used in resecting a distal femur in a one-compartment joint replacement. The device includes first and second support members (12;5), at least one rod-like transverse coupler (10;12), and a guide template (20). The support members each include a support surface (3;6) that is adjustable to lie in one plane (1) and designed to bear against one condyle (24;25) of a femur (21). The transverse coupler is arranged parallel to a transverse axis (2), which, in its end portion, is connected to the first support member (12) and is releasably connectable to the second support member (5). The transverse axis (2) extends parallel to a plane (1). The guide template (20) is displaceable parallel to the plane (1) relative to the second support member (5) and releasably lockable thereon.

Abstract: The invention relates to an electrooptical liquid crystal display comprising a reorientation layer for reorientation of the liquid crystals. The field of said reorientation layer has a component parallel to the liquid crystal layer, said component being crucial for the reorientation. Said component comprises a liquid-crystalline medium having a positive dielectric anisotropy and contains at least one mesogenic compound of the formula (I), wherein R1 and L are delined as in claim 1.

Abstract: The present invention is concerned with a novel process for the preparation of 1-(3,5-bis(trifluoromethyl)phenyl)ethan-1-one (CAS 30071-93-3). This compound is useful as an intermediate in the synthesis of therapeutic agents.

Abstract: The present invention relates to tetrakisfluoroalkylborate salts, methods of producing same, and their use in electrolytes, batteries, capacitors, supercapacitors, and galvanic cells.

Abstract: An assay is performed such that a compendium of raw assay data is developed and is then positionally corrected. The assay comprises a plurality of longitudinally oriented plates p, each having a wells organized into rows i and columns j. Each well (i, j, p) has a raw value xijp associated therewith that is deconstructed into: a plate effect value representing extraneous effects attributable to the plate p of the well (i, j, p); a row effect value representing extraneous effects attributable to the row i on the plate p of the well (i, j, p); a column effect value representing extraneous effects attributable to the column j on the plate p of the well (i, j, p); a non-additive, interaction effect representing extraneous positional effects attributable to consistent positional effects beyond the plate, row, and column effects previously determined for the (i, j, p) well on plate p; and a residual data value that is left over once all the above extraneous effects are taken into account.

Abstract: Chromanone derivatives of the formula I in which R1 to R4 are each, independently of one another, H, A, CN, Hal, OR5, COOR5, CF3, OCF3, NO2, Ar, OAr, N(R5)2 or CON(R5)2, R5 is H or A, A is alkyl having 1 to 6 carbon atoms, Ar is phenyl which is unsubstituted or substituted by A, OR5, CN, Hal, CF3, OCF3, NO2 or N(R5)2, Hal is F, Cl, Br or I, and their salts, are suitable as intermediates in the synthesis of medicaments.

Abstract: The invention relates to a novel enzyme, histidine protein phosphatase, which is derived from mammalian sources, and its homologue variants. The invention further relates to DNA sequences encoding said proteins, to a process for preparing the latter, and to antibodies directed against them. The novel phosphatase can be used for diagnosis of pathological states of cell regulation and cell growth and as pharmaceutical drug which can be administered in conjunction with pathological disorders related to malfunctions of said enzyme.

Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.

Abstract: The present invention is directed to compounds of the formula I: (wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n and the dashed line are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

Abstract: Compositions and pharmaceutical compositions are described which comprise: a component A comprising one or more flavonol glycosides, a component B comprising one or more tetrahydrofolic acid compounds, a component C comprising one or more calcium supplements, and a component D comprising one or more magnesium supplements. Methods of using such compositions and pharmaceutical compositions to treat and/or prevent osteoporosis and/or an inflammatory joint disease are also described.

Abstract: The invention relates to a triazole derivative with an activity inhibiting glycine transporter and for use as a pharmaceutical drug, and a novel triazole derivative. The inventive triazole derivative has an excellent activity inhibiting glycine transporter and is useful as a therapeutic agent of dementia, schizophrenia, cognitive disorders, or cognitive disorders involved in various diseases such as Alzheimer disease, Parkinson's disease, or Huntington disease or the like, or spasm involved in diseases such as nerve degenerative diseases and cerebrovascular disorders, or the like. Particularly, the pharmaceutical drug is useful for the amelioration of learning disability of dementia and the like.

Abstract: Compounds described by the chemical formula (I) or a pharmaceutically acceptable salt thereof: are inhibitors of p38 useful in the treatment of inflammatory diseases such as arthritis.

Abstract: A liquid-crystalline medium comprises the compound of the formula (I): generally in amounts from 1 to 30% by weight, preferably from 2 to 20% by weight, particularly preferably from 3 to 10% by weight, and further liquid-crystalline compounds.

Abstract: The present invention relates to oxabicyclooctanes of the general formula I. in which R1, R2, A1, A2, A3, A4, L1, L2, n1, n2 and n3 have the meanings specified in claim 1, and to their use in liquid-crystalline media.

Abstract: The invention relates to a liquid-crystalline medium which is characterized in that it comprises one or more compounds of the formula A and one more compounds of the formula B in which Ra, Rb, Rbb, x and L1 are as defined in claim 1.